> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – September 2016

Loading EJC News Focus video

How to predict the outcome of prostate cancer

Decades of research into prostate cancer has failed to answer a key question: how do you distinguish between lethal and non-lethal disease? A global team, headed by Freddie Hamdy (University of Oxford, UK), is setting up a trial which could, finally, give clear pointers.

In this EJC News Focus, he tells Helen Saul about the ProtecT trial which is about to report on the effectiveness of surgery, external beam radiotherapy and active monitoring in 80,000 men. This unique cohort of men has made possible the new Prostaid trial. Hamdy and his colleagues believe that lethality and non-lethality signatures are hidden in the samples stored in the first trial. These signatures could answer the pressing questions routinely faced by men and their physicians.

Hamdy was speaking at the Annual Symposium of Cancer Research UK (CRUK)'s Oxford Centre. His group have been shortlisted for funding for Prostaid in the CRUK Grand Challenge Awards.